Atai Life Sciences
Prezzo: 3.92Società e modello di business
Atai Life Sciences is a biotechnology company focused on developing innovative treatments for mental health disorders. Its core products include psychedelic compounds and therapies aimed at addressing conditions such as depression and anxiety. The company operates primarily in the healthcare sector, with major revenue sources stemming from research collaborations, licensing agreements, and potential future product sales.
Profilo di investimento
The investment profile of Atai Life Sciences is more aligned with growth investors, given its focus on developing novel therapies and the potential for significant market impact. However, the company's current financial performance indicates higher risk, making it less suitable for conservative investors seeking stable returns. The stock may appeal to those with a medium to long-term investment horizon, as it navigates the complexities of drug development and regulatory approval.
Metriche fondamentali (sperimentale)
- EPS (TTM) — utile per azione degli ultimi 12 mesi, $
- -3.00 Rischio
- Ricavi QoQ — crescita dei ricavi trimestre su trimestre
- -10.5% ↓
- Sorpresa EPS
- 27.3% meglio del previsto
- Volatilità 20g
- 4.3% stabile
Traccia in portafoglio
Grafico prezzo
| Data | Prima | Dopo | Motivo |
|---|---|---|---|
| 2026-06-05 02:55 | Mantieni | Vendi | Weak fundamentals and high risk limit upside potential. |
| 2026-05-28 02:35 | Vendi | Mantieni | Weak fundamentals and high risk limit upside potential. |
| 2026-05-20 02:35 | Mantieni | Vendi | scenario_deterioration |
| Data | Analista | Action | Target | Prezzo allora |
|---|---|---|---|---|
| 2026-04-20 11:57 | Canaccord Genuity | Target alzato | 14 → 15 | 5.2 |
| 2026-03-27 08:52 | Deutsche Bank | Aggiorna | — → 12 | 3.35 |
| 2026-03-06 20:37 | Jefferies | Aggiorna | — → 10 | 3.39 |
Ancora nulla